Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis.
- Mysore S Anil Kumar,
- Kim Papp,
- Ryo Tainaka,
- Udaya Valluri,
- Xuegong Wang,
- Tong Zhu,
- Christian Schwabe
Biopharm Drug Dispos 2018 Apr 21. Epub 2018 Apr 21.
Auckland Clinical Studies Ltd, Auckland, New Zealand.
This study evaluated pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab - a fully-human anti-CD40 monoclonal recombinant IgG4. Patients with moderate-to-severe psoriasis were randomized on Day 1 to receive bleselumab or placebo on Days 1, 15, and 29 in a dose-escalation of bleselumab 0.1, 0. Read More